UNSPSC 51332702: Clocapramine

This classification denotes an antidepressant agent with the molecular formula C28H37ClN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6EEL1GB72K, chemically known as 3-chloro-5-(3-(4-piperidino-4- carbamoylpiperidino)propyl)-10,11-dihydro-5h- dibenz(b,f)azepine dihydrochloride monohydrate but generally known as clocapramine, which bears US NIH Compound Identifier 2793. European Medicines Agency schedules Clocapramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06683MIG.

UNSPSC 51332702 Clocapramine is a Commodity code that in practice covers pharmaceutical products procured by state and local health authorities, though recent state and local opportunities under this code tag a broader range of pharmaceutical and drug-management procurement than the code name alone suggests. State and local governments buy naloxone and drug deactivation systems for community health programs, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and are exploring direct-to-manufacturer prescription fulfillment programs to improve cost management and efficiency in pharmacy benefit delivery. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances that serve multiple state and local jurisdictions. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have all solicited under or related to this code in recent months.

Geographic activity spans Florida, Texas, and Minnesota, with MMCAP's cooperative arrangement extending to Oregon and other participating jurisdictions. A recent representative opportunity is Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the response deadline was July 26, 2023. The Minnesota Department of Administration issued MMCAP RFP S1070000015802 on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with awarded vendors effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities and market intelligence for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's intent to gather information before issuing a formal RFP. Vendors must typically certify cGMP and DSCSA compliance, maintain insurance coverage including workers' compensation and professional liability, and comply with E-Verify and federal regulations where FEMA or other federal funding is involved.